TAB1 Antibody [Unconjugated]

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

TAK1-binding protein 1 (TAB1), also known as MAP3K7IP1, is an activator of the MAP3K TAK1. The C-terminal 68 amino acids of TAB1 are sufficient for binding and activation of TAK1, while a portion of the N-terminus acts as a dominant-negative inhibitor of TGF-beta , suggesting that TAB1 may function as a signaling intermediate between TGF-beta receptors and TAK1. TAB1 also promotes autophosphorylation and activation of the MAPK p38 alpha .

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 1 confirmed species: Human.

We have publications tested in 1 application: ICC.

Showing Publications 1 - 2 of 2.

Publications using AF3578	Applications	Species
Ortiz B, Driscoll A, Menon R et al. Chlamydia trachomatis antigen induces TLR4-TAB1-mediated inflammation, but not cell death, in maternal decidua cells American journal of reproductive immunology (New York, N.Y. : 1989) 12/9/2022 [PMID: 36495029]
Zhao D, Zheng HQ, Zhou Z The Fbw7 tumor suppressor targets KLF5 for ubiquitin-mediated degradation and suppresses breast cell proliferation. Cancer Res., 2010-05-18;70(11):4728-38. 2010-05-18 [PMID: 20484041] (ICC, Human)	ICC	Human

Array AF3578

• TAB1 Antibodies
• TAB1 Lysate
• TAB1 Proteins